Biography
Education and qualifications
1982: PhD, University of London, Supervisor Lorna Casselton
1978: BSc, Genetics and Microbiology (First Class Honours), University of London
Appointments
2002-present: Director, Beatson Institute for Cancer Research, Glasgow
1999-2002: Laboratory Chief, NCI-FCRDC, USA
1998-1999: Interim Director, ABL Basic Research Programme, USA
1995-1998: Laboratory Director, ABL Basic Research Programme, USA
1987-1995: Group Head, Ludwig Institute for Cancer Research, London
1985-1987: Visiting Fellow with Doug Lowy, NCI, USA
1981-1985: Postdoctoral Fellow with Chris Marshall, ICR, London
Honours and awards
Elected to Board of Directors, AACR, 2012
Commander of the British Empire (Services to Clinical Science), 2010
Fellow of the European Academy of Cancer Sciences, 2009
Royal Society of Edinburgh Gold Medal, 2009
The Sir Frederick Gowland Hopkins Memorial Medal Lecture, 2008
The Mike Price Lecture, 2008
Honorary DSc, University of Strathclyde, 2008
Fellow of the Academy of Medical Sciences, 2006
Honorary DSc, University of London, 2006
Fellow of the Royal Society of Edinburgh, 2004
Member of EMBO, 2004
Tom Connors Award Lecture, BACR, 2003
Wellcome Trust Lecture, BSCB, 2003
Fellow of the Royal Society, 2003
NIH Merit Award for Major Contributions to Research, 2001
Tenovus Gold Medal for Contributions to the Field of Gene Expression, 1998
Recent Publications
2013
Cheung
E,
Athineos
D,
Lee
P,
Ridgway
R,
Lambie
W,
Nixon
C,
Strathdee
D,
Blyth
K,
Sansom
O,
Vousden
KH.
TIGAR
is
required
for
efficient
intestinal
regeneration
and
tumorigensis.
Dev
Cell, in
press
2013
Maddocks ODK, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53 dependent metabolic remodeling in cancer cells. Nature 493: 542-6, 2013
Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe
PV, Nixon C, Karim SA, Caswell PT, Noll JE, Coffill CR, Lane DP, Sansom
OJ, Neilsen PM, Norman JC, Vousden KH. Mutant p53 enhances MET
trafficking and signalling to drive cell scattering and invasion.
Oncogene 32(10): 1252-65, 2013
Trinidad
AG,
Muller
PA,
Cuellar
J,
Klejnot
M,
Nobis
M,
Valpuesta
JM,
Vousden
KH.
Interaction
of
p53
with
the
CCT
complex
promoted
protein
folding
and
wild
type
p53
activity.
Mol
Cell, in
press
2013
Berkers
C,
Maddocks
O,
Cheung
E,
Mor
I,
Vousden
KH.
Metabolic
regulation
by
p53
familty
members.
Cell
Metabolism, in press
2013
Hock
AK,
Vousden
KH.
The
role
of
ubiquitin
modification
in
the
regulation
of
p53.
BBA
Mol
Cell
Res, in
press
2013
Muller PA, Vousden KH. p53 mutations in cancer. Nature Cell Biol 15: 2-8, 2013
2012
Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. PNAS 109: 20491-6, 2012
Roxburgh P, Hock AK, Dickens MP, Mezna M, Fischer PM, Vousden KH. Small
molecules that bind the Mdm2 RING stabilize and activate p53.
Carcinogenesis 33: 791-8, 2012
Hock AK, Vousden KH. Tumor Suppression by p53: Fall of the Triumvirate? Cell 149: 1183-5, 2012
Chaneton B, Hillmann P, Zheng L, Martin ACL, Maddocks ODK, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O’Reilly M, Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M1. Nature 491: 458-462, 2012
Coffill CR, Muller PA, Oh HK, Neo SP, Hogue KA, Cheok CF, Vousden KH, Lane DP, Blackstock WP, Gunaratne J. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep 13: 638-44, 2012
Dolezelova P, Cetkovska K, Vousden KH, Uldrijan S. Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability. FEBS Lett 586: 2225-31, 2012
Dolezelova P, Cetkovska K, Vousden KH, Uldrijan S. Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers. Cell Cycle 11(5): 953-62, 2012
Dou H, Buetow L, Hock A, Sibbet GJ, Vousden KH, Huang DT. Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl. Nat Struct Mol Biol 19: 184-92, 2012
Rainero E, Caswell PT, Muller PA, Grindlay J, McCaffrey MW, Zhang Q, Wakelam MJ, Vousden KH, Graziani A, Norman JC. Diacylglycerol kinase alpha controls RCP-dependent integrin trafficking to promote invasive migration. J Cell Biol 196: 277-95, 2012
Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dotsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, Takahashi N, Vandenabeele P, Knight RA, Levine AJ, Melino G. Loss of p53 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. PNAS 109: 15312-7, 2012
2011
Hock AK, Vigneron AM, Carter S, Ludwig RL,
Vousden KH.
Regulation of p53 stability and function by the
deubiquitinating enzyme USP42. EMBO J 2011; 30:
4921-30
Stindt MH, Carter S, Vigneron AM, Ryan KM,
Vousden KH.
MDM2 promotes SUMO-2/3 modification of p53
to modulate transcriptional activity. Cell Cycle
2011;10: 3176-88
Vigneron AM, Vousden KH.
An indirect role for ASPP1 in limiting p53-
dependent p21 expression and cellular senescence.
EMBO J doi: 10.1038/emboj.2011.402 * Nov 2011
Cao Y, DePinho RA, Ernst M, Vousden K.
Cancer research: past, present and future. Nature Rev
Cancer 2011; 11: 749-54
Maddocks OD, Vousden KH (2011). Metabolic regulation by p53. J Mol Med. 89, 237-45. Erratum in: J Mol Med. 89, 531.
Marshall C, Vousden K.
Genetic and cellular mechanisms of oncogenesis.
Curr Opin Genet Dev 2011; 21: 1-3
Mor I, Cheung EC, Vousden KH.
Control of Glycolysis through Regulation of PFK1:
Old Friends and Recent Additions. Cold Spring Harb
Symp Quant Biol doi:10.1101/sqb.2011.76.010868,
published online 17 Nov 2011
Muller PA, Vousden KH, Norman JC (2011). p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 192, 209-18.
2010
Vigneron AM, Ludwig RL, Vousden KH (2010).
Cytoplasmic ASPP1 inhibits apoptosis through the
control of YAP. Genes Dev. 24, 2430-9
.
Croft DR, Crighton D, Samuel MS, Lourenco FC, Munro J, Wood J, Bensaad K, Vousden
KH, Sansom OJ, Ryan KM, Olson MF (2010).
p53-mediated transcription and activation of the
actin cytoskeleton regulatory RhoC to LIMK2
signaling pathway promotes cell survival. Cell Res. 21, 666-82.
O'Prey J, Crighton D, Martin AG, Vousden KH,
Fearnhead HO, Ryan KM (2010).
p53-mediated induction of Noxa and p53AIP1
requires NFkappaB. Cell Cycle 9, 947-52.
Cheung EC, Vousden KH (2010).
The role of p53 in glucose metabolism. Curr Opin
Cell Biol. 22, 186-91.
Hock A, Vousden KH (2010).
Regulation of the p53 pathway by ubiquitin and
related proteins. Int J Biochem Cell Biol. 42,
1618-21.
Vigneron A, Vousden KH (2010).
p53 and Mdm2: an auld alliance. Cell Cycle 9,
865-6.
Vigneron A, Vousden KH (2010).
p53, ROS and senescence in the control of aging.
Aging 2, 471-4.
Vousden KH (2010).
Alternative fuel - another role for p53 in the
regulation of metabolism. Proc Natl Acad Sci USA
107, 7117-8.
2009
Bensaad K, Cheung EC, Vousden KH (2009). Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J. 28, 3015-26.
Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327-41.
Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH (2009). PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 16, 1135-45.
Carter S, Vousden KH (2009). Modifications of p53: competing for the lysines. Curr Opin Genet Dev. 19, 18-24.
Galluzzi L
et al. (2009). Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 16, 1093-107.
Gottlieb E and Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect. a001040, published online 2 Dec 2009.
Vousden KH (2009). Functions of p53 in metabolism and invasion. Biochem Soc Trans. 37, 511-7.
Vousden KH, Prives C (2009). Blinded by the Light: The Growing Complexity of p53. Cell 137, 413-31.
Vousden KH, Ryan KM (2009). p53 and metabolism. Nat Rev Cancer 9, 691-700.
2008
Carter S, Vousden KH (2008). p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 7, 2519-28.
Horn HF, Vousden KH (2008). Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 27, 5774-84.
Yee KS, Vousden KH (2008). Contribution of membrane localization to the apoptotic activity of PUMA. Apoptosis 13, 87-95.
Carter S, Vousden KH (2008). A role for Numb in p53 stabilization. Genome Biology 9, 221.
The p53 protein plays an important role in protecting from cancer. In part, this reflects its ability to inhibit proliferation or eliminate cells that have the potential for malignant progression but more recently, we have found that p53 can also contribute to protecting cells from DNA damage. 
Vousden Scientific Report 2012 (
